Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Valion Bio (TIVC) EBITDA Margin (2021 - 2025)

Valion Bio has reported EBITDA Margin over the past 5 years, most recently at 1700.68% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 56497.0% year-over-year to 1700.68%; the TTM value through Sep 2025 reached 1536.51%, down 86546.0%, while the annual FY2024 figure was 725.77%, 2466.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 1700.68% at Valion Bio, up from 2248.84% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 327.24% in Q1 2021 and troughed at 2248.84% in Q2 2025.
  • A 5-year average of 867.75% and a median of 589.2% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: soared 41559bps in 2024 and later plummeted -170802bps in 2025.
  • Year by year, EBITDA Margin stood at 589.2% in 2021, then rose by 6bps to 552.94% in 2022, then dropped by -14bps to 628.57% in 2023, then crashed by -31bps to 823.89% in 2024, then tumbled by -106bps to 1700.68% in 2025.
  • Business Quant data shows EBITDA Margin for TIVC at 1700.68% in Q3 2025, 2248.84% in Q2 2025, and 2151.43% in Q1 2025.